Charles Schwab Investment Management Inc Supernus Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $521 Billion
- Q1 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 746,149 shares of SUPN stock, worth $23.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
746,149
Previous 753,363
0.96%
Holding current value
$23.7 Million
Previous $27.2 Million
10.3%
% of portfolio
0.0%
Previous 0.01%
Shares
31 transactions
Others Institutions Holding SUPN
# of Institutions
305Shares Held
60.8MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$331 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$196 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$165 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$92.4 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.7MShares$85.9 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.7B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...